^
    Back
    Association details:
    Biomarker:PIK3CA mutation
    Cancer:Breast Cancer
    Drug Class:CDK4 inhibitor +
    CDK6 inhibitor
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    Source:
    Pharmacol Res
    Title:

    PI3K mutations detected in liquid biopsy are associated to reduced sensitivity to CDK4/6 inhibitors in metastatic breast cancer patients

    Published date:
    10/10/2020
    Excerpt:
    ABC patients were enrolled...PIK3CA mutation status at baseline was independently associated with shorter median PFS (7.44 vs 12.9 months, p = 0.01) in subject receiving CDK4/6i plus hormone therapy treatment.
    DOI:
    10.1016/j.phrs.2020.105241